Stella Opens Flagship PTSD Treatment Location in Chicago and Secures $7M in Funding
Summary
The capital raise will be used to advance Stellas industry leading mental health research and open locations across the US and abroad.Stella, a (Sterling) portfolio company, also unveiled its new flagship facility in Chicago, which will serve as a hub for innovative treatments, research, and medical training including hosting clinical trials and uncovering effective, science-backed treatment protocols and methodologies.Founded in 2020, Stella has treated over 6,000 patients to date. Stella targets the physical injury caused by mental trauma with biological interventions and is most widely known for Dr Lipovs advanced Stellate Ganglion Block (SGB) protocol, the (DSR). DSR consists of two injections of local anesthetic next to a bundle of fight or flight nerves in one side of the neck to reset the nervous system and alleviate PTSD symptoms. Our Chicago flagship represents the next step in our journey to expand clinical research efforts, and bring hope and healing to even more struggling individuals.This new round comes as Stella experiences rapid growth, treating 40% more patients in Q1 2023 as compared to the previous quarter, and administering treatment at over 35 partner locations across the U.S., Israel, and Australia. Our clinical leadership will continue to lead the way in neurological trauma care and uncover effective, science-backed protocols that can improve the lives of countless patients around the world.